MedTrace Logo

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

NCT07123090 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-03-25

No results posted yet for this study

Summary

The goal of this research study is to evaluate how well and safely the study drugs sasanlimab, palbociclib, and axitinib work for treatment of participants with advanced clear cell renal cell carcinoma (ccRCC) or translocation renal cell carcinoma (tRCC).

The name of the study drugs involved in this research study is:

* Sasanlimab (a type of monoclonal antibody)
* Palbociclib (a type of kinase inhibitor)
* Axitinib (a type of Vascular endothelial growth factor inhibitor)

Conditions

  • Metastatic Renal Cell Carcinoma
  • Metastatic Renal Cancer
  • Renal Cell Carcinoma
  • Advanced Clear Cell Renal Cell Carcinoma
  • Kidney Cancer
  • Translocation Renal Cell Carcinoma

Interventions

DRUG

Sasanlimab

Recombinant humanized monoclonal antibody, prefilled syringe, subcutaneous (under the skin) injection per protocol

DRUG

Palbociclib

Cyclin-dependent kinase (CDK) 4/6 inhibitor, tablet taken orally per protocol

DRUG

Axitinib

Vascular endothelial growth factor (VEGF) inhibitor, tablet taken orally per standard of care

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Stephanie Berg

    lead OTHER

Principal Investigators

  • Stephanie Berg, DO · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-24
Primary Completion
2026-10-01
Completion
2028-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07123090 on ClinicalTrials.gov